Clinical Trials Sponsored by ABL Bio, Inc.

Total 437 results

ABL Bio, Inc.

Recruiting

This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants

Healthy

United States
ABL Bio, Inc.

Recruiting

A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors

Advanced Solid Tumor

Korea, Republic of
ABL Bio, Inc.

Recruiting

Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Advanced Solid Tumor

Korea, Republic of
ABL Bio, Inc.

Recruiting

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects With Any Progressive Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumor

Korea, Republic of, United States
ABL Bio, Inc.
National OncoVenture

Completed

This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001

Advanced Solid Tumors

Korea, Republic of
Handok Inc.
ABL Bio, Inc.; Compass Therapeutics

Active, not recruiting

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

P1b: Advanced Solid Tumors | P2: Biliary Tract Cancer

Korea, Republic of
AB2 Bio Ltd.

Completed

Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease

Still's Disease, Adult-Onset

Germany, France, Switzerland
AB2 Bio Ltd.

Completed

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

NLRC4-MAS | XIAP Deficiency

United States, Canada, Germany
AB2 Bio Ltd.

Active, not recruiting

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension

NLRC4-MAS | XIAP Deficiency

United States, Canada, Germany
Karo Bio AB

Completed

LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin

Dyslipidemia

Sweden
Karo Bio AB

Completed

LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe

Hypercholesterolemia

Sweden
Karo Bio AB

Completed

Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia

Primary Hypercholesterolemia

Sweden
Karo Bio AB

Terminated

Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care (AKKA)

Heterozygous Familial Hypercholesterolaemia
Tourmaline Bio, Inc.

Not yet recruiting

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP (TRANQUILITY)

Chronic Kidney Diseases | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | C-Reactive Protein | Chronic Renal Diseases | Kidney Insufficiency, Chronic | hsCRP | High Sensitivity C-Reactive Protein | Hs-CRP
Envivo Bio Inc

Recruiting

Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®

Small Intestinal Bacterial Overgrowth

United States
Qlaris Bio, Inc.

Not yet recruiting

Qlaris Phase 2 Study in NTG Patients

Glaucoma | Normal Tension Glaucoma (NTG) | Low-Tension Glaucoma, Bilateral | Low-Tension Glaucoma, Unspecified Eye

Korea, Republic of, Philippines
Exai Bio Inc.

Recruiting

Prospective Study of oncRNA Stratification of Cancer by Size and Stage

Cancer

United States
Federation Bio Inc.

Recruiting

Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

Healthy | Enteric Hyperoxaluria

United States
CAGE Bio Inc.

Not yet recruiting

Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis

Atopic Dermatitis
Massive Bio, Inc.

Recruiting

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Melanoma | Follicular Lymphoma | Carcinoma | Myelodysplastic Syndromes | Leukemia | Cancer | Breast Cancer | Myeloproliferative Disorders | Glioblastoma | Myelofibrosis | Ovarian Cancer | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Neuroendocrine Tumors | Non Small Cell Lung Cancer | COVID | Non Hodgkin Lymphoma | Cholang... and other conditions

United States
Annovis Bio Inc.

Completed

A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

Alzheimer Disease

United States
Gasherbrum Bio, Inc

Active, not recruiting

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

Healthy Volunteers

United States
Passage Bio, Inc.

Active, not recruiting

Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis (Imagine-1)

GM1 Gangliosidosis | GM1 Gangliosidosis, Type I | GM1 Gangliosidosis, Type 2 | Beta-Galactosidase-1 (GLB1) Deficiency

United States, Canada, United Kingdom, Turkey, Brazil
Gritstone bio, Inc.

Active, not recruiting

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

United States
Takara Bio Inc.

Active, not recruiting

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer.

Pancreatic Cancer Stage IV | Pancreatic Cancer Stage III

Japan
Belite Bio, Inc

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects With STGD1 (DRAGON)

Stargardt Disease 1

United States, Australia, Belgium, China, France, Germany, Hong Kong, Netherlands, Switzerland, Taiwan, United Kingdom
Inmune Bio, Inc.

Withdrawn

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Mental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurodegenerative Diseases | Dementia | Mild Cognitive Impairment (MCI) | Alzheimer Disease | Tauopathies
Sesen Bio, Inc.

Completed

Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG (VISTA)

Bladder Cancer

United States, Canada
Gasherbrum Bio, Inc

Completed

A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants

Healthy Volunteers

United States
Qlaris Bio, Inc.

Completed

A Study to Evaluate Safety and Tolerability of QLS-101 in NTG

Normal Tension Glaucoma (NTG)

United States
AmMax Bio, Inc.

Active, not recruiting

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

Tenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis

Poland, Ukraine, United States, Netherlands
Teres Bio, Inc.

Completed

Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
Provention Bio, Inc.

Completed

PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers (PROVENT)

Viral; Infection, Coxsackie(Virus)

Finland
Xequel Bio, Inc.

Completed

A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery

Scar | Breast Reconstruction | Scarring | Mammoplasty

United States
Daewoong Bio Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of rhEGF Eye Drops in Healthy Male Subjects

Dry Eye Syndromes

Korea, Republic of
Provention Bio, Inc.

Completed

Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease (PRINCE)

Crohn's Disease

Austria, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine
Gritstone bio, Inc.

Completed

A Study of Personalized Neoantigen Cancer Vaccines

Colorectal Cancer | Non Small Cell Lung Cancer | Gastroesophageal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Urothelial Carcinoma

United States
Xequel Bio, Inc.

Completed

Study to Evaluate the Safety of FSR Peptide Versus Placebo Following Punch Biopsy

Wound Heal

Switzerland
Translate Bio, Inc.

Withdrawn

Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency (STEP-OTC)

Ornithine Transcarbamylase Deficiency
Lexent Bio, Inc.

Unknown

Detection of Tumor DNA in Blood Samples From Cancer Patients

Cancer | Tumors

United States
Takara Bio Inc.

Completed

A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions

Solid Tumor

Japan
Sesen Bio, Inc.

Terminated

Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

Head and Neck Cancer | Head and Neck Neoplasms | Carcinoma, Squamous Cell | Squamous Cell Carcinoma of the Head and Neck | Neoplasms, Squamous Cell | Mouth Neoplasms

United States, Canada
Lotus Bio Inc.

Unknown

Efficacy Evaluation of a Novel Diagnostic Assay Which is the Basis for Seaforia Diagnostic System

Male Fertility

Israel
Adicet Bio, Inc

Not yet recruiting

A Phase 1 Study of ADI-001 in Lupus Nephritis

Autoimmune Diseases | Lupus Nephritis
Nuvation Bio Inc.

Recruiting

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

Pancreatic Cancer | Advanced Solid Tumor | HER2-negative Breast Cancer | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Platinum-resistant Ovarian Cancer (PROC)

United States
Qlaris Bio, Inc.

Recruiting

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

Glaucoma | Open-angle Glaucoma (OAG) | Ocular Hypertension (OHT)

United States
Tourmaline Bio, Inc.

Recruiting

A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 75 Years of Age With Thyroid Eye Disease (spiriTED)

Thyroid Eye Disease

United States, Jordan
Qlaris Bio, Inc.

Recruiting

Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients

Primary Open Angle Glaucoma of Both Eyes | Primary Open Angle Glaucoma (POAG) | Primary Open-Angle Glaucoma, Unspecified Eye | Ocular Hypertension (OHT)

United States
Belite Bio, Inc

Recruiting

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy (PHOENIX)

Geographic Atrophy

United States, Taiwan, Australia, China, United Kingdom
Inmune Bio, Inc.

Recruiting

A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (LAUREL)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Cancer | AML | MDS-EB

Greece, United Kingdom

Clinical Trials Sponsored by ABL Bio, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations